Bonneville R et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017;2017:10.1200/PO.17.00073. Abstract
Buza N. HER2 testing in endometrial serous carcinoma. Arch Pathol Lab Med 2020;[Online ahead of print]. Abstract
Chung HC et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37(17):1470-8. Abstract
Drew Y et al. Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). ESMO 2019;Abstract 1190PD.
Fader AN et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): Updated overall survival analysis. Clin Cancer Res 2020;26(15):3928-35. Abstract
Green AK et al. A review of immune checkpoint blockade therapy in endometrial cancer. ASCO Educational Book 2020;40:1-7. Abstract
Konstantinopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5(8):1141-9. Abstract
Lheureux S et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. ASCO 2020;Abstract 6010.
Makker V et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020;38(26):2981-92. Abstract
Matulonis UA et al. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. ASCO 2020;Abstract 6005.
Mayadev J et al. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer 2020;30(7):1065-70. Abstract
O’Malley DM et al. Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study. ESMO 2019;Abstract 1044P.
Zamarin D et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRG oncology study. J Clin Oncol 2020;38(16):1814-23. Abstract